Nazarin Nasara An Buga a cikin Jini: Maganin CAR-T na CD7 da aka Ba da Nanobody don Cutar Leukemia Mai Tsanani

Ƙungiyar Likitoci ta Lu Daopei ta yi wani gagarumin ci gaba a fannin ilimin jinin jini. A ƙarƙashin jagorancin Dr. Lu Peihua, bincikensu mai ban mamaki, "Antigen na Chimeric da aka Zaɓa ta hanyar Nanobody" wanda aka Yi Niyya ga CD7 T Cell Mai Ragewa Maganin Cutar Leukemia Mai Tsanani "Myeloid Leukemia", kwanan nan aka buga a cikin mujallar da ta shahara a duniya Jini (Matsayin Tasiri: 21). Wannan bincike ya nuna wata hanya mai sauyi wajen magance cutar sankarar myeloid mai tsanani (AML), wadda ke nuna inganci da aminci wajen kashe ƙari yayin da take samar da sabuwar fata ga marasa lafiya da suka sake kamuwa da cutar AML ko kuma suka sake yin rashin lafiya.

Tsarin kirkire-kirkire
Binciken ya fara amfani da ƙwayoyin CAR-T na CD7 da aka gina a jikin nanobody a cikin maganin AML. Magungunan gargajiya na CAR-T galibi suna amfani da gutsuttsuran masu canzawa guda ɗaya (scFv) waɗanda aka samo daga ƙwayoyin rigakafi na monoclonal (mAbs). Wannan binciken ya yi amfani da ƙwayoyin rigakafi na nanobodies—ƙwayoyin rigakafi guda ɗaya da aka samo daga ƙwayoyin rigakafi masu nauyi na camel. Kwayoyin cuta na Nanobodies, saboda ƙaramin girmansu (15kDa idan aka kwatanta da IgG na ɗan adam na 150kDa) da raguwar garkuwar jiki, suna samar da ingantaccen takamaiman antigen da haɗin gwiwa yayin da suke rage tasirin illa.

NS7CAR-T mai tushen nanobody ya nuna ingantaccen ingancin maganin ƙari da aminci a gwaje-gwajen da suka gabata da na asibiti. Sakamakon da aka samu kafin a fara amfani da shi ya nuna cewa yaɗuwar ƙwayoyin halitta da kuma aikin hana ƙari sun fi kyau idan aka kwatanta da ƙwayoyin CAR-T masu tushen scFv. Bugu da ƙari, a cikin gwajin asibiti na Mataki na I, maganin ya sami cikakkiyar ƙimar sassaucin kashi 70% a tsakanin marasa lafiya 10 masu dauke da AML masu CD7, tare da kashi 60% sun sami ƙarancin yanayin rashin lafiya (MRD)-negative.

Tasirin Asibiti
Gwajin ya yi wa marasa lafiya da ke da manyan cututtuka, ciki har da waɗanda aka yi musu dashen ƙwayoyin halitta na jini a baya (allo-HSCT) ko kuma hanyoyin magani da yawa. Duk da waɗannan ƙalubalen, maganin NS7CAR-T da aka yi wa nanobody ya cimma sakamako mai kyau tare da illolin da za a iya shawo kansu, ciki har da ciwon sakin cytokine mai sauƙi (CRS) a cikin kashi 80% na mahalarta. Ba a ga wani lamari na guba a jijiyoyi ba.

Umarni na Nan gaba
Binciken ya jaddada buƙatar yin manyan gwaje-gwaje don ƙara tabbatar da inganci da amincin maganin CD7 CAR-T na nanobody a cikin maganin AML. Hakanan yana nuna ƙalubale kamar asarar antigen na CD7, wanda ya kasance babban cikas a cikin shari'o'in da suka sake dawowa. Magance waɗannan batutuwa zai zama mabuɗin inganta maganin don aikace-aikacen asibiti masu faɗi.

Sabuwar Horizon don Maganin AML
AML, wani nau'in cutar kansa mai sarkakiya da kuma bambancin jini, ya daɗe yana haifar da ƙalubale wajen cimma sassauci mai ɗorewa da kuma inganta yawan rayuwa gaba ɗaya. Wannan sabon abu da ƙungiyar likitocin Lu Daopei ta gabatar ba wai kawai yana ba da sabuwar hanyar magani ga marasa lafiya ba, har ma yana ƙarfafa shahararsu a fannin ilimi a binciken ilimin jini a duniya.

Wannan muhimmin ci gaba yana nuna jajircewar ƙungiyar wajen cike gibin bincike da kuma ayyukan asibiti. Yayin da ƙungiyar ke ci gaba da binciken magunguna masu inganci, aikinsu yana kawo sabon bege ga marasa lafiya a duk faɗin duniya kuma yana share fagen ci gaba mai ɗorewa a fannin ilimin jini.